JT

Jim Tananbaum

Founder of Foresite Capital Management

San Francisco, California

Overview 

Jim Tananbaum is the Founder and CEO of Foresite Capital, a venture capital firm specializing in investments in healthcare and biotechnology companies. With a background in entrepreneurship and a track record of successful investments, he has played key roles in founding and leading companies like Theravance and GelTex, and has invested in notable firms such as DNAnexus and Insitro. Tananbaum's career highlights include co-founding Theravance, which achieved significant success, and being a key figure in the acquisition of GelTex by Genzyme for $1.6 billion.

Work Experience 

FC

Foresite Capital Management

  • Founder and CEO

    2010 - Current

    Founder, CEO and managing director of a multi-stage healthcare and life sciences investment firm, and chief architect of its rigorous scientific and data-driven approach to investment analysis. Foresite Capital aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles.

Foresite Capital is a healthcare and life sciences investment firm.

foresitecapital.com

Prospect Venture Partners

  • Co-Founder and Managing Director PVP2 & PVP3

    2001 - 2010

    $1B healthcare venture capital group focussed on series A financings.

T(

Theravance (THRX)

  • Co-Founder and Chief Executive Officer

    1997 - 2000

    http://www.theravance.com/ and http://www.inva.com/

Theravance Biopharma is a biopharmaceutical company with one approved product.

Raised $663,200,000.00 from Woodford Investment Management.

theravance.com
SV

Sierra Ventures

  • Partner

    1994 - 1997

    Built Healthcare Service Investment practice. Led investments in Amerigroup, Healtheon, CareSelect (through Intensiva), and Novamed.

Sierra Ventures is an early-stage venture firm investing globally with a focus on next generation enterprise and emerging technologies.

sierraventures.com

GelTex (acquired Genzyme $1.6 B)

  • Co-Founder. Board Member.

    1991 - 1997

    Founded GelTex while finishing my Harvard degree, running the firm out of my garage for the first year. I recruited co-founder Professor George Whitesides from the Harvard Chemistry Department. Their product, Renvela, has helped more patients with renal failure than almost any drug in the world since its conception in 1991. The GelTex team also conceived of Cholestogel, which helped patients with high cholesterol that could not take other cholesterol reducing products. GelTex was sold to Genzyme, which was bought by Sanofi.

M

Merck

  • Product Manager, Prilosec

    1991 - 1993

    Primary architect of Prilosec GP strategy. Developed marketing campaign around promoting the use of Prilosec on patients with symptoms that had been treated with H2 antagonists (the previous market leaders). Pioneered using physician identified perscription data to focus marketing campaign on MDs that were top anti-ulcer prescribers.

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.

Raised $5,586,000.00 from Private Capital Advisors.

merck.com

Education 

Investments 

Alumis

Series A

Total funding: $330M

Genomics

Series Unknown

Total funding: $84M

Foresight Diagnostics

Series B

Total funding: $72M

evonetix

Series B

Total funding: $66M

Articles About Jim

Relevant Websites